Review of Hyperuricaemia and Hypertension: A Target for Treatment

Claudine G Jennings, Isla S Mackenzie and Thomas M MacDonald
Dundee University, Medicines Monitoring Unit, Ninewells Hospital, Dundee DD1 9SY, USA

Keywords: Hypertension; Hyperuricaemia; Cardiovascular risk

Introduction

Hypertension is a leading risk factor for cardiovascular disease and worldwide prevalence of hypertension is increasing. In 2000 26% of the world’s adult population (over 1 billion people) were considered to have hypertension and in 2009 the WHO reported that hypertension had a causative role in the deaths of over 7.5 million people [1,2] Prevalence of hypertension in adults of 16 years or older in the UK was 31.5% in men and 29.0% in women in 2010 [3]. The majority of hypertension is considered to be essential hypertension which develops due to a complex interplay of genetic, lifestyle and environmental factors. Cardiovascular risk associated with increasing blood pressure is continuous with 7% increase in mortality from ischaemic heart disease and 10% increased risk of mortality from stroke for every 2 mmHg rise in population blood pressure [4].

Therefore even small improvements in population blood pressure control are likely to have a significant impact on long term public health. Significant efforts are directed at addressing hypertension as a cardiovascular risk factor and one area that has fallen in and out of favour over the years is the role of hyperuricaemia in the development of hypertension and as a potentially modifiable cardiovascular risk factor. There is a growing body of evidence supporting the association between hyperuricaemia and the metabolic syndrome [5], chronic kidney disease [6] and atherosclerosis [7] as well as hypertension which will be the focus of this review. The question that now needs to be answered is whether there is a role for actively lowering serum urate levels to better manage these associated conditions. Small trials have been conducted looking at whether reduction of serum urate levels influences blood pressure control and there is now a growing consensus that a large randomised controlled trial is needed to finally answer this question [8].

PubMed, Web of Science and Medline databases were searched using the terms hyperuricaemia, uric acid, urate, hypertension, blood pressure, cardiovascular, xanthine oxidase inhibitor, uricosuric, allopurinol and febuxostat in English language publications from 1975 to July 2013. Abstracts were reviewed by category and references retrieved for papers meeting relevance criteria, reference lists of selected papers were scrutinised for relevant papers and data synthesised by themes [9].

Definition of Hyperuricaemia

Uric acid is the end product of purine metabolism in humans and increased serum urate levels may be seen due to high dietary purine intake (particularly shellfish, red meat and beer), in conditions of increased cell turnover or cell death (for example following cytotoxic chemotherapy) and if renal function is impaired (urate is approximately 70% renally excreted). Urate levels generally rise with increasing age and hyperuricaemia is also seen in the metabolic syndrome partly due to hyperinsulinemia impairing urate excretion [10]. The definition of hyperuricaemia varies but is generally considered to be levels above the serum saturation point of uric acid (approximately 6.8 mg/dL). Above this level uric acid may precipitate out of solution and be deposited in joints and tissues causing the recognised complication of gout. Guidelines for the management of gout recommend achieving serum urate levels below 6 mg/dL in order to reduce gout flares and complications [11]. There are currently no guidelines or recommendations for the management of asymptomatic hyperuricaemia.

Hyperuricaemia and Evolution

Hyperuricaemia is an almost uniquely human problem due to the fact that humans have a loss of function mutation affecting the uricase enzyme which prevents further breakdown of uric acid into more soluble waste products. This mutation occurred over 15 million years ago, during a time of intense climatic upheaval when food, water and salt supplies were scarce, and resulted in significantly higher serum urate levels in humans than in most other mammals. This mutation is thought to have conferred an evolutionary advantage by enabling our early ancestors to retain sodium, maintain blood pressure with a salt poor diet and augment fat storage from fructose found in fruits
Historical Association of Hyperuricaemia and Hypertension

Hyperuricaemia is currently viewed solely as an important risk factor in the development of gout but is not otherwise routinely measured or monitored. Historically, however, hyperuricaemia has been closely associated with elevated blood pressure, for example, a paper published in the Lancet in 1879 noted that many gout patients were hypertensive and a subsequent BMJ review of "arterial tension" in 1889 recommended a low purine diet for the management of hypertension [15,16]. Hyperuricaemia fell out of favour as a cardiovascular risk factor in the 1970’s and 80’s (and consequently measurement of serum urate was removed from many standard blood testing panels) partly due to the lack of evidence of a causal association and partly due to concerns regarding side effects of medication used to manage what was considered to be an asymptomatic condition.

The establishment of plausible biological mechanisms for the relationship between hyperuricaemia and hypertension has been facilitated by the development of animal models of hyperuricaemia. This information, coupled with large observational studies in human populations have provided a growing body of evidence pointing strongly to a causal relationship between hyperuricaemia and the development of hypertension [17].

Biological Mechanisms for Hyperuricaemia Induced Hypertension

The first animal models of hyperuricaemia were developed in the 1990’s and used oxonic acid as an uricase inhibitor. Initial work in rats showed that after 2 weeks exposure to mild increases in urate levels, there was activation of the renin angiotensin system and decrease in plasma nitrates leading to vasoconstriction and hypertension [18]. This hypertension was reversible by either stopping the oxonic acid (allowing the uricase enzyme to function normally) or by lowering urate levels with either xanthine oxidase inhibitors or uricosuric agents. This early hypertension was also responsive to treatment with blockade of the renin-angiotensin system [19].

When hyperuricaemia was induced in normal and remnant kidney rats it resulted in renal cortical vasoconstriction, glomerular hypertension and inflammatory cell infiltration, and the vascular damage recorded was much more severe in the remnant kidney rats. It was surmised that in this model, hyperuricaemia impaired the autoregulatory responses of afferent arterioles resulting in glomerular hypertension and vascular wall thickening to produce renal hypoperfusion. This led to renal ischaemia and subsequent tubulointerstitial inflammation, fibrosis and arterial hypertension [20]. Importantly these effects were not seen in rats treated with allopurinol which prevented the rise in urate levels.

Evidence from Epidemiological studies

Since the revival of interest in the role of hyperuricaemia in the development of hypertension and as a potential independent cardiovascular risk factor, there has been an exponential rise in the number of papers published demonstrating and discussing this link [24]. Two recent meta-analyses looking specifically at hyperuricaemia and hypertension have concluded that higher urate levels predict the development of hypertension. Meta-analysis by Zhang and colleagues in 2009 included their prospective cohort study of 7220 normotensive Chinese patients with 4 years follow up. The adjusted relative risk of developing hypertension was 1.55 in men and 1.91 in women for the highest quartiles of serum urate compared with the lowest quartiles. When included with 7 other studies in the meta-analysis (total 28,657 participants) there was a pooled relative risk of 1.55 for development of hypertension in those with the highest quartiles of serum urate. In Zhang’s original study the association between hyperuricaemia and hypertension appeared to be partly mediated by abdominal obesity and it was postulated that this was due to hyperinsulinemia enhancing uric acid reabsorption [25]. In 2011 Grayson conducted a meta-analysis of 18 published, prospective cohort studies (including the 8 studies used by Zhang) comprising a total of 55,607 patients (Table 1 ) [25-42]. This meta-analysis showed that hyperuricaemia was associated with an increased risk for incident hypertension (adjusted
risk ratio 1.41) and for every 1 mg/dl increase in serum urate the pooled risk ratio for incident hypertension (after correcting for confounding factors) was 1.13. The risk appeared to be more significant in younger people and in women [23]. These two meta-analyses included studies from Europe, China, Japan, Israel and the USA indicating that this relationship is seen across ethnic groups.

<table>
<thead>
<tr>
<th>Author</th>
<th>Population</th>
<th>Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forman [29]</td>
<td>Nurses Health Survey (US), n=1496</td>
<td>OR for incident hypertension 1.89; 95% CI 1.26-2.82</td>
</tr>
<tr>
<td>Zhang [27]</td>
<td>Qingdao Port Health and Nutrition 7220 Examination Survey in China, mean age 37</td>
<td>Adjusted RR for incident hypertension men 1.55; 95% CI 1.10-2.19 and women 1.91; 95% CI 1.12-3.25</td>
</tr>
<tr>
<td>Forman [30]</td>
<td>Health Professionals Follow up Study (US), n=1454 (men only)</td>
<td>Adjusted RR 1.24; 95% CI 0.93 to 1.66</td>
</tr>
<tr>
<td>Krishnan [31]</td>
<td>Multiple Risk Factor Intervention Trial (US), n=3073</td>
<td>Hazard ratio 1.81; 95% CI: 1.59 to 2.07 for incident hypertension</td>
</tr>
<tr>
<td>Mellen [32]</td>
<td>Atherosclerosis Risk in Communities (ARIC) study (US), n=9104</td>
<td>Adjusted hazard ratio for incident hypertension for each SD of higher uric acid 1.10; 95% CI 1.04 to 1.15</td>
</tr>
<tr>
<td>Perlstein [33]</td>
<td>Normative Aging Study (US), n=2062</td>
<td>Age adjusted RR 1.10; 95% CI: 1.06 to 1.15</td>
</tr>
<tr>
<td>Shankar [34]</td>
<td>Beaver Dam Population Cohort (US), n=2520</td>
<td>RR for incident hypertension 1.65; 95% CI 1.41-1.93</td>
</tr>
<tr>
<td>Sundstrom [28]</td>
<td>Framingham (US), n=3329</td>
<td>Adjusted OR for incident hypertension 1.17; 95% CI 1.02-1.33 for every 1 SD increase in SUA</td>
</tr>
<tr>
<td>Nagahama [35]</td>
<td>Okinawa General Health Maintenance Association (OGHMA) cohort (Japan), n=4469</td>
<td>Adjusted OR for incident hypertension, men 1.48; 95% CI 1.08-2.02, women 1.90; 95% CI 1.03-3.51</td>
</tr>
<tr>
<td>Nakanishi [36]</td>
<td>Male office workers (Japan), n=2310</td>
<td>Adjusted RR for incident hypertension 1.58; 95% CI 1.26-1.99</td>
</tr>
<tr>
<td>Taniguchi [37]</td>
<td>Osaka Health Survey (Japan), n=6356</td>
<td>Adjusted RR incident hypertension 2.01; 95% CI 1.56-2.59</td>
</tr>
<tr>
<td>Imazu [38]</td>
<td>Hawai, Los Angeles Hiroshima Study (US/Japan), n=159</td>
<td>Adjusted RR for incident hypertension 2.03; 95% CI 1.02-3.90</td>
</tr>
<tr>
<td>Dyer [39]</td>
<td>Coronary Artery Risk Development in Young Adults (CARDIA) study (US), n=4747</td>
<td>Multivariate OR for incident hypertension, black men 1.21; 95% CI 1.03-1.41, white men 1.16; 95% CI 0.96-1.40</td>
</tr>
<tr>
<td>Jossa [40]</td>
<td>Olivettic Heart Study (Italy), n=505</td>
<td>Adjusted RR for incident hypertension 1.23; 95% CI 1.07-1.39</td>
</tr>
<tr>
<td>Hunt [41]</td>
<td>Utah Cardiovascular Genetics Study (US), n=1482</td>
<td>Adjusted RR for incident hypertension 2.16 (p&lt;0.10)</td>
</tr>
<tr>
<td>Selby [42]</td>
<td>Kaiser Permanente Multiphasic Health Checkup (US), n=2062</td>
<td>RR for incident hypertension 2.19; 95% CI 1.2-3.98</td>
</tr>
<tr>
<td>Fessel [43]</td>
<td>Target population and screening program (US), n=335</td>
<td>Data not available</td>
</tr>
<tr>
<td>Kahn [44]</td>
<td>The Israel Ischaemic Heart Disease Study, n=2904</td>
<td>RR for incident hypertension 1.82; 95% CI 1.3-2.54</td>
</tr>
</tbody>
</table>

Table 1: Studies used in Grayson meta-analysis linking hyperuricaemia and hypertension, [Abbreviations: RR: Relative Risk, OR: Odds Ratio, HR: Hazard Ratio, CI: Confidence Interval, SUA: Serum Uric Acid Level]

Other studies not included in the above meta-analyses include the Bogalusa Heart study which looked at 577 US children, followed up for a mean of 11.4 years and showed that childhood urate levels significantly predicted hypertension in adult life [43]. The Taiwanese Health Survey from 2012 comprising 3257 patients showed that high serum urate was an independent predictor of blood pressure progression (HR 1.78) and incident hypertension (HR 1.68) [44]. A small Turkish study looking at 112 hypertensive patients with 24 hr ABPM readings, categorised patients as dippers or non-dippers depending on blood pressure fall during the night. Loss of nocturnal blood pressure dipping is associated with worse cardiovascular outcomes and in this study the non-dippers had significantly higher urate levels than the dippers (OR 2.28) [45].

The epidemiological evidence to date does indicate a strong association between hyperuricaemia and hypertension and the diversity of ages and ethnic groups studied and the length of follow up lend weight to the argument that this association is causal, rather than representative of two conditions that share the same risk factors. However, epidemiological evidence does not provide conclusive proof of causality and further experimental work and evidence from interventional trials are required to firmly establish the nature of this relationship.

Management of Hyperuricaemia – Clinical Trial Data

If hyperuricaemia is accepted as a potential causal factor for the development of essential hypertension then does reducing serum urate levels protect against the development of hypertension? A number of clinical trials over the past decade have sought to answer this question through either lowering urate levels with xanthine oxidase inhibitors or through use of uricosuric agents. The method by which urate lowering is achieved is important when looking at outcomes. Uricosuric agents such as probenecid act via the renal tubules and lower urate levels by increased renal excretion. Xanthine oxidase inhibitors (XOi) act by blocking the conversion of hypoxanthine to xanthine (the precursor of uric acid) and generally have a more potent
Another trial compared 30 asymptomatic hyperuricaemic patients and 30 normouricaemic controls and showed that systolic blood pressure reduction was comparable despite different blood pressure reductions [53]. It was hypothesised that hyperuricaemia in hypertensive patients and particularly adolescents could be mitigated by urate lowering therapy [49].

Small pilot studies have been undertaken using allopurinol in hypertensive patients and particularly striking results have been seen in obese and newly diagnosed adolescents with hypertension. A randomised, placebo controlled trial in US adolescents with newly diagnosed essential hypertension showed that allopurinol 200mg twice daily resulted in a mean 24 hr blood pressure change of -6.3 mmHg systolic and -4.6 diastolic compared to 0.8 systolic and -0.3 diastolic for the placebo group. These changes were significant although limited by the small sample size of only 30 adolescents [48]. A further study in 60 pre-hypertensive obese 11-17 year olds found that those treated with allopurinol had a blood pressure reduction of 3.3 mmHg and diastolic blood pressure by 1.3 mmHg. They concluded that this could have been due to the uricosuric action of allopurinol with 37 asymptomatic hyperuricaemic patients [52]. The evidence looking at hyperuricaemia and cardiovascular outcomes shows mixed results. The European Working Party on High Blood Pressure in the elderly found no relationship between urate levels and cardiovascular outcomes however the patients studied were enrolled in a trial of diuretics which may have confounded the results [57]. Data from the Framingham Heart study which included 6763 Framingham participants with measurements of serum urate taken between 1971 and 1976 showed that after adjusting for other risk factors, urate levels did not predict adverse cardiovascular outcomes. The authors concluded that elevated serum urate does not have a causal role in the development of coronary heart disease, death from cardiovascular disease, or death from all causes [58]. A meta-analysis of 11 trials involving 21,373 participants looking at changes in serum urate and cardiovascular events found that there was no relationship between changes in urate levels and outcomes [59]. The authors acknowledged that hyperuricaemic patients are at increased risk of cardiovascular events however as many of the risk factors for hyperuricaemia are the same risk factors as for cardiovascular disease the difficulty remains in separating out the individual effect of hyperuricaemia [59-61]. This also confirms the ongoing doubt surrounding the best management of hyperuricaemia as evidence that aggressive treatment of hyperuricaemia improves overall cardiovascular outcomes is lacking.

Conclusions

Undoubtedly the effect of hyperuricaemia in the human body is complex. At present evidence is accumulating that hyperuricaemia could be a significant factor in the development of hypertension in some people, and importantly, hyperuricaemia is also a potentially
reversible risk factor. Hypertension is a significant global health problem and a key contributor to increased risk of cardiovascular events, therefore any intervention that could improve the management of hypertension requires careful examination. There remains an unanswered question over whether aggressive management of hyperuricaemia can reduce blood pressure and improve cardiovascular outcomes significantly enough to be cost effective and outweigh the potential side effects of the urate lowering therapies required. Large randomised controlled trials are needed to answer this question, and it is possible that in the future management of hyperuricaemia will be as routine as management of cholesterol in the context of modifying cardiovascular risk.

References


J Hypertens
ISSN:2167-1095 JHOA, an open access journal

Volume 3 • Issue 4 • 1000164


